



Septiembre – Noviembre

Dr. Álvaro Fredes



INDISA - NEORED
Un Nuevo Concepto en Medicina Perinatal



Comparison of the management recommendations of the Kaiser Permanente neonatal early-onset sepsis risk calculator (SRC) with NICE guideline CG149 in infants \geq 34 weeks' gestation who developed EOS

- **Método:** retrospectivo, 5 centros Inglaterra y Gales. Aplicación virtual de ambas guías (NICE vs SRC) en 70 RN \geq 34 con sepsis precoz confirmada por cultivos (HC o LCR) y tratada al menos 5 días con ATB.
- Se excluyen CoNS (contaminación).
- **Outcome:** número de RN en los que se recomienda usar ATB antes de las 4 horas de vida.

Indicaciones para screening y tratamiento de EOS (NICE 2012)

Factores de riesgo materno para EOS

'Red Flags'

Parentral antibiotic treatment given to the woman for confirmed or suspected invasive bacterial infection (such as septicaemia) at any time during labour, or in the 24-hour periods before and after the birth [This does not refer to intrapartum antibiotic prophylaxis]

Suspected or confirmed infection in another baby in the case of a multiple pregnancy

'Non-Red Flags'

Invasive group B streptococcal infection in a previous baby

Maternal group B streptococcal colonisation, bacteriuria or infection in the current pregnancy

Prelabour rupture of membranes

Preterm birth following spontaneous labour (before 37 weeks' gestation)

Suspected or confirmed rupture of membranes for more than 18 hours in a preterm birth

Intrapartum fever higher than 38°C, or confirmed or suspected chorioamnionitis

Indicadores clínicos en RN

'Red Flags'

Respiratory distress starting more than 4 hours after birth

Seizures

Need for mechanical ventilation in a term baby

Signs of shock

'Non-Red Flags'

Altered behaviour or responsiveness	Need for cardio-pulmonary resuscitation
Altered muscle tone (for example, floppiness)	Need for mechanical ventilation in a preterm baby
Feeding difficulties (for example, feed refusal)	Persistent fetal circulation (persistent pulmonary hypertension)
Feed intolerance, including vomiting, excessive gastric aspirates and abdominal distension	Temperature abnormality (lower than 36°C or higher than 38°C) unexplained by environmental factors
Abnormal heart rate (bradycardia or tachycardia)	Unexplained excessive bleeding, thrombocytopenia, or abnormal coagulation (INR greater than 2.0)
Signs of respiratory distress	Oliguria persisting beyond 24 hours after birth
Hypoxia (for example, central cyanosis or reduced oxygen saturation level)	Altered glucose homeostasis (hypoglycaemia or hyperglycaemia)
Jaundice within 24 hours of birth	Metabolic acidosis (base deficit of ≥ 10 mmol/litre)
Apnoea	Local signs of infection (for example, affecting the skin or eye)
Signs of neonatal encephalopathy	

Indicaciones para screening y tratamiento de EOS (NICE 2012)

- Factores de riesgo maternos:
 - 2 non-red flags
 - 1 red flag
- Indicadores clínicos en RN:
 - 2 non-red flags
 - 1 red flag

* RN sin red flags y sólo 1 FR materno o indicador clínico, uso de juicio clínico y considerar:

- No iniciar ATB
- Monitorizar SV y condición clínica al menos por 12 horas (0, 1h y 2h, luego cada 2h)

Sepsis Risk Calculator (2018)

Predictor	Scenario
Incidence of Early-Onset Sepsis ?	<input type="text"/>
Gestational age ?	<input type="text"/> weeks <input type="text"/> days
Highest maternal antepartum temperature ?	<input type="text"/> Fahrenheit <input type="button" value="°C"/>
ROM (Hours) ?	<input type="text"/>
Maternal GBS status ?	<input type="radio"/> Negative <input type="radio"/> Positive <input type="radio"/> Unknown
Type of intrapartum antibiotics ?	<input type="radio"/> Broad spectrum antibiotics > 4 hrs prior to birth <input type="radio"/> Broad spectrum antibiotics 2-3.9 hrs prior to birth <input type="radio"/> GBS specific antibiotics > 2 hrs prior to birth <input type="radio"/> No antibiotics or any antibiotics < 2 hrs prior to birth

Calculate »
Clear

Risk per 1000/births

EOS Risk @ Birth	
------------------	--

EOS Risk after Clinical Exam	Risk per 1000/births	Clinical Recommendation	Vitals
Well Appearing			
Equivocal			
Clinical Illness			

Classification of Infant's Clinical Presentation Clinical Illness Equivocal Well Appearing

Sepsis Risk Calculator (2018)

Clinical Exam	Description
Clinical Illness	<ol style="list-style-type: none">1. Persistent need for NCPAP / HFNC / mechanical ventilation (outside of the delivery room)2. Hemodynamic instability requiring vasoactive drugs3. Neonatal encephalopathy /Perinatal depression<ul style="list-style-type: none">▪ Seizure▪ Apgar Score @ 5 minutes < 54. Need for supplemental O₂ ≥ 2 hours to maintain oxygen saturations > 90% (outside of the delivery room)
Equivocal	<ol style="list-style-type: none">1. Persistent physiologic abnormality ≥ 4 hrs<ul style="list-style-type: none">▪ Tachycardia (HR ≥ 160)▪ Tachypnea (RR ≥ 60)▪ Temperature instability (≥ 100.4°F or < 97.5°F)▪ Respiratory distress (grunting, flaring, or retracting) not requiring supplemental O₂2. Two or more physiologic abnormalities lasting for ≥ 2 hrs<ul style="list-style-type: none">▪ Tachycardia (HR ≥ 160)▪ Tachypnea (RR ≥ 60)▪ Temperature instability (≥ 100.4°F or < 97.5°F)▪ Respiratory distress (grunting, flaring, or retracting) not requiring supplemental O₂ <p>Note: abnormality can be intermittent</p>
Well Appearing	No persistent physiologic abnormalities

Table 1 Incidence of early-onset sepsis in babies born ≥ 34 weeks' gestation

Centre	Cases of EOS $\geq 34+0$ gestation (n)	Total births $\geq 34+0$ gestation during study period per unit	Incidence per 1000 births	Study period	Background incidence used in calculator
Swansea	19	25 930	0.7	2008–2017	0.6*
Bath	18	46 859	0.4	2008–2016	0.5
Exeter	12	30 447	0.4	2009–2016	0.5
Cornwall	19	31 061	0.6	2010–2016	0.6
Glan Clwyd	4	8036	0.5	2015–2017	0.5
Total	72	142 333	0.5		

*At time of study the highest background incidence available to use on sepsis risk calculator (SRC) was 0.6, but higher rates are now available.

EOS, early-onset sepsis.

Table 2 Organisms identified

Organism	n
Group B <i>Streptococcus</i>	63 (1 later excluded)
<i>Escherichia coli</i>	2
<i>Streptococcus mitis</i>	2
<i>Haemophilus influenzae</i>	1
<i>Staphylococcus aureus</i>	2 (1 later excluded)
<i>Streptococcus anginosus</i>	1
<i>Streptococcus viridans</i>	1
Total	72 (2 later excluded)

Table 3 Infant characteristics

	All infants	Treated by NICE	Treated by SRC	Untreated by 4 hours
	Total 70	Total 39 55.7%	Total 27 38.6%	Total 31 44.3%
	n (%)	n (%)	n (%)	n (%)
Gestation ≥34 to <37 weeks (n)	9 (12.9%)	6 (15.4%)	4 (14.8%)	3 (9.7%)
Maternal temperature ≥38°C (n)	10 (14.3%)	10 (25.6%)	4 (14.8%)	0
Mean ROM (hours)	23	29	24	15
ROM ≥24 hours (n)	24 (34.3%)	19 (48.8%)	9 (33.3%)	6 (19.4%)
Maternal GBS (n) status by 4 hours				
Negative	6 (8.6%)	1 (2.6%)	1 (3.7%)	5 (16.1%)
Positive	4 (5.7%)	4 (10.3%)	0	0
Unknown	60 (85.7%)	34 (87.2%)	26 (96.3%)	26 (83.9%)
Intrapartum antibiotics (n)				
Broad spectrum >4 hours prior to birth	2 (2.9%)	2 (5.1%)	0	0
Broad spectrum 2–3.9 hours prior to birth	6 (8.6%)	6 (15.4%)	2 (7.4%)	0
GBS specific >2 hours prior to birth	4 (5.7%)	4 (10.3%)	2 (7.4%)	0
None or <2 hours prior to birth	58 (82.9%)	27 (69.2%)	23 (85.2%)	31 (100%)
≥1 NICE red flag (n)	29 (41.4%)	29 (74.4%)	25 (92.6%)	0
1 NICE risk factor (n)	30 (42.9%)	19 (48.7%)	17 (63%)	11 (35.5%)
≥2 NICE risk factors (n)	18 (25.7%)	18 (46.2%)	8 (29.6%)	0
None of the above	20 (28.6%)	0	0	20 (64.5%)

Table 3 Infant characteristics

	All infants	Treated by NICE	Treated by SRC	Untreated by 4 hours
	Total 70	Total 39	Total 27	Total 31
	n (%)	n (%)	n (%)	n (%)
Clinical illness category to 4 hours (n)				
Well	43 (61.4%)	13 (33.3%)	1 (3.7%)	30 (96.8%)
Equivocal	1 (1.4%)	0	0	1 (3.2%)
Unwell	26 (37.2%)	26 (66.7%)	26 (96.3%)	0
CRP in the first 4 hours				
Number of values	41 (58.6%)	38 (97.4%)	26 (96.3%)	3 (9.7%)
Mean	11.8	12.4	13	4
Median (range)	3 (0.1–64)	3 (0.1–64)	2.1 (0.1–64)	3 (1–8)
CRP>10 (n)	13 (18.6%)	13 (33.3%)	9 (33.3%)	0()
Max CRP				
Number of values	68 (97.1%)	38 (97.4%)	26 (96.3%)	30 (96.8%)
Mean	79.2	61.5	72	103.1
Median (range)	61.5 (3–300)	52 (3–154)	61.5 (10–154)	85 (4–300)
CRP>10 (n)	60 (85.7%)	33 (84.6%)	25 (92.6%)	27 (87.1%)

Conclusiones





- 81% de los RN con EOS comprobada presentó síntomas dentro de las primeras 24h.
- Antes de las cuatro horas ambas guías son malos predictores de sepsis para al menos 2/3 de los RN.
- Más pacientes serían identificados con la guía NICE (17.1%).

Basic principles of neonatal bubble CPAP: effects on CPAP delivery and imposed work of breathing when altering the original design


- **Objetivo:** evaluar efectos de cambios en modelo original de bCPAP (1) resistencia interfase nasal, (2) volumen de espacio muerto, (3) diámetro/resistencia de rama exhalatoria.
- **Método:** modelo de pulmón mecánico, medición de PEEP entregado y trabajo respiratorio impuesto.

Table 1 bCPAP design variations


	Interface resistance	Dead space	Expiratory tubing resistance	Comment
Sahni and Wung ⁵	Low	Low	Low	Used in several trials and manuscripts; Fisher & Paykel bCPAP has a similar design
Audu et al ⁸	High	Low	High	Description of modified oxygen cannula (figures 1–3) later used in clinical trial
Brown et al ³¹	Low	High	Low*	Description of the first version of the Pumani CPAP (figure 1)
Daga et al ⁹	High	Low	High	Clinical trial using modified oxygen cannula with seal (figures 1–5)
Duket ¹⁰	High	Low	High	Review including modified oxygen cannula (figures 2 and 3). Other designs: original bCPAP (figure 1) and high-resistance interface (RAM type, figure 5).
Kawaza et al ³²	Low	High	Low*	Clinical trial including Pumani first version, reference to Brown et al
Chisti et al ¹¹	High	Low	High	Randomised trial including modified oxygen cannula, reference to Duke
McAdams et al ²³	High	Low	Unknown	Case series and description of bCPAP with high-resistance interface (RAM type) (figure 2)
Ezenwa et al ¹²	High	Low	High	Retrospective observational study using modified oxygen cannula (figures 1 and 2)
WHO ¹³	High	Low	High	Manual including modified oxygen cannula (figures 15 and 16). Other designs: original CPAP (figure 14).
Bennett et al ³³	High	High	Low*	Description of a bCPAP system with a high-resistance interface (RAM type) and connector tube similar to Brown et al (figure 1)
Falk et al ³⁰	Low	Low	High	Description of the second version of the Pumani CPAP (figure 2)
Bjorklund et al ³⁹	High	Low	High	Clinical trial using modified oxygen cannula with seal (figure 1)
Thaddanee et al ¹⁴	High	Unknown	High	Observational trial and description of two modified oxygen cannula systems (figures 1 and 2).
Amadi et al ¹⁵	High	Low	High	Observational trial and description of modified oxygen cannula systems (figure 1)



PEEP entregado



Trabajo Respiratorio




Conclusiones

- Cánula corta y máscara nasal son las interfases recomendadas.
- Cánula RAM no está aprobado por FDA, uso off-label.
- Uso de cánula RAM con sello completo de narinas y boca provoca resistencia muy alta.

The practice of blood volume submitted for culture in a neonatal intensive care unit

- Volumen óptimo para hemocultivo:
 - 1 ml
 - BD BACTEC 1-3 ml
 - < 0.5 ml sensibilidad desconocida
- **Objetivo:** evaluar impacto de QI para mejorar volumen de sangre de hemocultivo e identificar factores que determinan muestras subóptimas.
- **Método:** peso de frasco de HC pre y post inoculación de sangre.

- 637 muestras (130 pre-intervención y 507 post intervención).
- Previo a intervención el 3.1% de los HC tenía volumen óptimo, mediana (IQR) 0.36 (0.23) mL.
- Post intervención el 75% de los HC tiene volumen óptimo, mediana (IQR) 0.9 (0.27) mL.
 - 93.2% de muestras subóptimas fue debido a dificultad para refluir catéter.








Table 2 Proportion of positivity with optimal and suboptimal blood volume

Nature of organism	Optimal volume (n=385)	Suboptimal volume (n=252)	P value
Pathogen	21/385=5.5%	11/252=4.4%	0.54
Contaminant	2/385=0.5%	8/252=3.2%	0.008

Total number of cultures 637.

¿Relación entre volumen subóptimo y contaminación de la muestra?

Table of contents: September 2020 - Vol 105 - 5

- Drainage, irrigation and fibrinolytic therapy (DRIFT) for posthaemorrhagic ventricular dilatation: 10-year follow-up of a randomised controlled trial
- Faecal volatile organic compounds in preterm babies at risk of necrotising enterocolitis: the DOVE study
- Propofol for endotracheal intubation in neonates: a dose-finding trial
- Thyroid function in preterm infants and neurodevelopment at 2 years
- Prophylactic hydrocortisone in extremely preterm infants and brain MRI abnormality

Table of contents: November 2020 - Vol 105 - 6

- Umbilical cord milking in preterm infants: a systematic review and meta-analysis
- Economic evaluation alongside the Speed of Increasing milk Feeds Trial (SIFT)
- Regional brain volumes, microstructure and neurodevelopment in moderate–late preterm children
- Low risk of necrotising enterocolitis in enteraly fed neonates with critical heart disease: an observational study
- Blue LED phototherapy in preterm infants: effects on an oxidative marker of DNA damage